Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer.
Invest New Drugs
; 27(2): 120-3, 2009 Apr.
Article
em En
| MEDLINE
| ID: mdl-18553054
ABSTRACT
PURPOSE:
To evaluate the anti-glycolytic effects of 3-BrPA on rats bearing RMT mammary tumors, by determining FDG uptake after intravenous administration of the therapeutic dose. MATERIALS ANDMETHODS:
Sixteen rats bearing RMT tumors were treated either with 15 mM 3-BrPA in 2.5 ml of PBS or with 2.5 ml of PBS. After treatment, all rats received FDG and were sacrificed 1 h later.RESULTS:
3-BrPA treatment significantly decreased FDG uptake in tumors by 77% (p = 0.002). FDG uptake did not significantly decrease in normal tissues after treatment.CONCLUSION:
Our study showed that 3-BrPA exhibits a strong anti-glycolytic effect on RMT cells implanted in rats.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piruvatos
/
Fluordesoxiglucose F18
/
Glicólise
/
Neoplasias Mamárias Experimentais
Limite:
Animals
Idioma:
En
Revista:
Invest New Drugs
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Estados Unidos